L arge space-occupying infarction in the territory of the middle cerebral artery (MCA), also known as malignant MCA stroke, is a life-threatening neurological disease. The development of massive brain edema secondary to the ischemic injury usually leads to brain tissue shifts and transtentorial herniation within a few days. [1] [2] [3] [4] [5] [6] In patients 60 years and younger, early hemicraniectomy has been shown to be effective in reducing mortality and severe disability, with numbers needed to treat of 2 and 4, respectively. Despite this remarkable treatment effect, every fifth patient dies in the early stage of the disease, and every third patient is left with moderate to severe disability after hemicraniectomy.
6-8
Therapeutic hypothermia is a potentially neuroprotective therapy with proven efficacy in clinical trials on global cerebral ischemia after cardiac arrest and animal models after focal cerebral ischemia. [9] [10] [11] [12] In focal cerebral ischemia, preclinical data and observational studies suggest that hypothermia is most effective if started early after vessel occlusion, if cooling level is moderately low (temperature, 32-33°C), and if duration of cooling is sufficiently long (>48 hours). [11] [12] [13] [14] There are only a few hypothermia studies in patients with malignant MCA stroke. In this disease, hypothermia is mainly an antiedema therapy. Although less effective than hemicraniectomy, moderate hypothermia (temperature, 32-33°C) reduced mortality to about 40% in observational studies compared with standard care. 8, 15 This treatment effect was consistent across different studies, settings, and durations of hypothermia (1 to 22 days). 8 In a small study, the combination of hypothermia (temperature, 35°C) for 2 days in addition to hemicraniectomy did not show an increased risk of severe adverse effects and complications warranting a larger randomized clinical trial.
15
Based on these data, it is suggestive that outcome in malignant MCA stroke could be further improved beyond the effects of early hemicraniectomy by simultaneous hypothermia according to an optimized protocol. Key elements of hypothermia in such a protocol are (1) early initiation after hemicraniectomy, (2) target level of cooling between 32°C and 34°C, (3) duration of hypothermia at least 72 hours, and (4) controlled induction, maintenance, and rewarming by feedback systems. 8 The present trial tests the hypothesis that hypothermia in addition to hemicraniectomy could reduce mortality in patients with malignant MCA stroke. The study used a randomized and controlled approach.
Methods

Study Design
The trial was conducted at 6 German university hospitals between August 2011 and September 2016. The institutional review boards of the Friedrich-Alexander University (Erlangen, Germany) and all participating centers approved the trial protocol. The trial had an open-label, randomized, controlled design. Blinded raters obtained follow-up-information after 12 months using a structured telephone interview. Further details can be found in the previously published protocol. 8 
Patients
Patients were eligible if they were aged 18 to 60 years, had clinical signs of unilateral MCA infarction with a score of more than 14 in cases of nondominant hemispheric stroke or a score of more than 19 in cases of dominant hemispheric stroke, and a reduced level of consciousness on the National Institutes of Health Stroke Scale (NIHSS) as used in previous randomized clinical trials of malignant MCA stroke. 6, 16 On neuroimaging, unilateral ischemia had to involve at least two-thirds of the MCA territory plus the basal ganglia. All patients were treated by early hemicraniectomy within 48 hours from symptom onset. Exclusion criteria were preexisting disability exceeding a score of 1 on the modified Rankin Scale (mRS) or preexisting impairment in the activities of daily living with values below 95 on the Barthel Index. Further exclusion criteria are listed in the eMethods in Supplement 1. All patients or their legal representatives provided written informed consent prior to randomization.
Randomization
Randomization was computer generated in blocks and stratified for centers using a web-based system (https://www. randomizer.at/). Patients were assigned in a 1:1 ratio to either standard care (control group) or therapeutic hypothermia (hypothermia group).
Procedures
All patients received early hemicraniectomy within 48 hours from symptom onset and were treated on an experienced neurointensive care unit receiving the best medical treatment available, in accordance with recommendations of current guidelines and protocols of recent trials. [16] [17] [18] [19] Core body temperature
was measured with bladder catheters in all patients. In the control group, the temperature was not allowed to be actively lowered beneath 36.5°C. Patients assigned to the hypothermia group received cooling with intravascular or surface cooling devices within 12 hours after hemicraniectomy to achieve a target temperature of 33.0 ± 1.0°C. Rapid induction of hypothermia with cooled saline solutions was allowed. Patients were intubated and sedated during induction and maintenance of hypothermia and during rewarming. Hypothermia was maintained for at least 72 hours, followed by controlled slow rewarming (0.05 to 0.1°C/hour).
Outcomes
The primary outcome was early mortality at day 14. Safety and feasibility end points were the rate of serious adverse events (SAEs) and treatment parameters concerning hypothermia. Pneumonia was considered an adverse event but not an SAE, because its rate in intubated patients in the intensive care unit is reported to be 70% even under normothermia. 20 Further key secondary end points were stroke severity on the NIHSS at day 14, functional outcomes on the mRS and Barthel Index at 12 months, and treatment parameters concerning hemicraniectomy and treatment in the intensive care unit. Analyses of secondary end points included patients who died.
Statistical Analysis
A total of 324 patients were planned to be included in this trial based on estimated mortality rates within 14 days of 20% in the control group and 8% in the hypothermia group (1−β=0.80,α=.05;Fisher exact test). Because data on the treatment effect of hypothermia are weak and sample size calculation was derived from only a single small observational study, an interim analysis was planned after inclusion of 50 patients. Successive safety monitoring was conducted after the treatment of every 10th patient and on advice of the data safety monitoring board. The trial was suspended on September 9, 2015. The final follow-up was completed on September 1, 2016.
Results are reported in accordance with the prespecified statistical analysis plan as intention to treat. For mortality at day 14 and tracheostomy at day 14, odds ratios with 95% CIs were calculated via conditional likelihood and compared with the Fisher test. Pneumonia, as the adverse event of special interest, was analyzed analogously after 14 days. Incidence rates for SAE occurrence were calculated with log-transformed 95% CIs. Times from onset of symptoms to decompressive hemicraniectomy were compared using the t test. Log-rank tests and Cox regression were used to compare ventilation times in both groups for the competing risk end points end of ventilation and death during ventilation. The duration of intensive care treatment was analyzed with the logrank test and Cox regression with the combined end point of the end of stay in intensive care (whether alive and discharged or dead in the intensive care unit). For recurring events such as days with medication while in intensive care, days with therapeutic ventilation, number of computed tomographic scans and/or magnetic resonance images while hospitalized, and days with osmotherapy, incidence rates with logtransformed 95% CIs were calculated, as well as hazard ratios, Nelson-Aalen estimators, and log-rank tests. Time-toevent end points after 12 months were analyzed using Cox proportional hazards model and log-rank tests. For SAEs, incidence rates with log-transformed 95% CIs were calculated and Cox proportional hazards model for competing risks (adverse events vs death without adverse events) was used. For functional outcome, the Wilcoxon rank sum test was used for group comparison of NIHSS scores after 14 days, Glasgow Coma Scale scores after 14 days, mRS dichotomized between 0 to 4 points vs 5 or 6 points after 12 months, and a shift analysis was applied to the mRS score after 12 months. Statistical analysis was performed using R version 1.1.423 (R Foundation for Statistical Computing). A data safety monitoring board monitored trial safety. Additional details of the statistical analysis plan are shown in Supplement 2.
Results
Of the projected 324 patients, 50 patients (26 in the hypothermia group and 24 in the control group) had been enrolled in the trial between August 2011 and September 2015. The Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Figure 1 . A first safety signal in terms of a higher rate of SAEs was observed after the treatment of 34 patients. Because of the overall low number of patients included in the trial, the data safety monitoring board suggested at that point to proceed until the preplanned interim analysis. However, no trend reversal concerning safety was observed. Therefore, the data safety monitoring board recommended stopping the trial after inclusion of 50 patients and proceeding with the final analysis instead of the interim analysis.
Baseline demographic and clinical characteristics are shown in Table 1 . Of the 26 patients in the hypothermia group, 14 (54%) were treated with endovascular cooling devices and 10 (38%) received surface cooling. One patient additionally received intravenous cooled saline (2%). Two patients randomized to hypothermia (8%) did not receive this treatment, 1 because of a subdural hematoma after decompressive hemicraniectomy and 1 because the senior anesthetist in charge refused to induce hypothermia after randomization. There were 2 other protocol violations; in each group, 1 patient underwent hemicraniectomy after 48 hours. One patient in each treatment group was lost to follow-up at 12 months. Figure 2A shows the body temperature course for both treatment groups throughout the first 14 days after randomization for the per-protocol population, excluding the 2 crossover patients. Curves are based on the mean temperature per day in each group. Patients were normothermic in both groups at the time of randomization at day 1 (control group temperature, 36.9°C ± 0.9°C; hypothermia group temperature, 36.5°C ± 1.2°C; P = .24). Hypothermia was induced after randomization at day 1. Target temperature was reached and maintained for a minimum of 72 hours in 21 of 24 patients (88%) treated with hypothermia. In 3 patients (12%), core body temperature was kept slightly higher than 34°C but did not reach the target temperature for a minimum of 72 hours (mean core body temperatures in these 3 patients were 34.1°C, 34.4°C, and 34.9°C). Median duration of hypothermia including rewarming was 7 days (interquartile range, 5-8 days) in the per-protocol population.
Temperature Measurements
Safety Measurements
After 14 days, SAEs were found in 12 of 26 patients (46%) in the hypothermia group and 7 of 24 patients (29%) in the con-trol group (OR, 2.05 [95% CI, 0.56-8.00]; P = .26) (eResults in Supplement 1). Rates of SAE that were associated with temperature management were 5 of 26 patients (19%) in the hypothermia group and 0 of 24 patients in the control group (0%; P = .05). For the first 14 days after hemicraniectomy, incidence rates of SAEs per day were 0.070 in the hypothermia group (23 of 327 patient-days) and 0.036 in the control group (11 of 309 patient-days; HR, 2.19 [95% CI, 0.97-4.94]; P = .06). The SAEs were then grouped according to the Common Terminology Criteria for Adverse Events (version 4.03; https:// evs.nci.nih.gov/ftp1/CTCAE) into cardiovascular disorders, nervous system disorder, respiratory disorders, and other disorders. Rates of SAEs in specific organ classes were not significantly different between the hypothermia group and control group (eTable in Supplement 1).
After 12 months, 20 of 25 patients (80%) had SAEs in the hypothermia group, and 10 of 23 (43%) had SAEs in the control group. Accordingly, incidence rates of SAEs per day were 0.006 in the hypothermia group and 0.002 in the control group (HR, 2.54 [95% CI, 1.29-5.00]; P = .005), in favor of the control group. Further data on safety measures are in Table 2 .
Early Mortality and Secondary Clinical End Points
There was no significant difference for the primary end point, mortality at day 14, between both groups. Five of 26 patients (19%) in the hypothermia group and 3 of 24 (13%) in the control group had died after 14 days (OR, 1.65 [95% CI, 0.28-12.01]; P = .70). There were also no significant differences between the 2 groups concerning mortality ( [95% CI, 1.43-4.58]; P = .001). There were no significant differences between the hypothermia group and the control group regarding other secondary end points. Primary and key secondary end points did not change in per-protocol and as-treated analyses. Sensitivity analyses confirmed the intent-to-treat analyses.
Discussion
The trial did not meet its primary end point; patients treated with hypothermia had no benefits regarding mortality at day 14. Most of the deaths in patients with malignant MCA stroke occurred early and were mainly based on herniation owing to severe brain edema and tissue shift, as has been shown in previous clinical studies on hypothermia and randomized trials on hemicraniectomy. The treatment effect of any effective therapy so far is therefore primarily based on the reduction of early mortality rather than the improvement of the functional outcome of survivors. 5, 6, 8, 15, 16 The primary end point was chosen to investigate whether the combination of 2 therapies targeting malignant brain edema and herniation is more effective to prevent early deaths than the current standard therapy of hemicraniectomy alone. The question whether hypothermia is beneficial in malignant stroke is controversial. Hypothermia seems to be of benefit compared with best medical treatment, yet it is far less effective than hemicraniectomy. 8 Since the publication of the positive trials on hemicraniectomy, hypothermia is often used in addition to hemicraniectomy in several centers. 14 However, evidence for this combined treatment is weak. The negative result of our study is in contrast with the promising results of 1 small randomized controlled trial and a recent retrospective case series, both of which share methodological weaknesses.
15,21
Our trial was stopped for safety reasons after enrollment of 50 patients at the time of the preplanned interim analysis. The trend toward a higher rate of SAEs within 14 days in the hypothermia group, which was first observed after treatment of 34 patients, persisted. The significantly higher rate of SAEs in the hypothermia group after 12 months of follow-up corroborates the decision to stop the trial. In addition to the lack of a positive effect on mortality, the trial thereby provides comparative evidence of potentially harmful effects of moderate hypothermia in addition to early hemicraniectomy. These negative results and the higher rate of SAEs are in accordance with negative trials on hypothermia in other severe neurological diseases as well as trials in patients who are awake with severe stroke and recent case series on malignant stroke.
22-29
Our results strongly suggest that the high rates of SAEs observed in this trial may be directly associated with hypothermic treatment, although SAEs may also be attributed to prolonged sedation during hypothermia or both. These data do not allow a more detailed analysis on causality owing to the small numbers of patients.
There were only a few significant differences between the treatment groups besides the rates of SAEs. The higher risk for mechanical ventilation in the hypothermia group may certainly be attributed to the fact that patients remained sedated and intubated during hypothermic treatment. The higher risk to receive osmotherapy in the hypothermia group corresponds well to the higher mean ICP levels in the hypothermia group. The major ICP peak at day 5 in the hypothermia group suggests that rebound edema occurred despite the slow rewarming protocol, while the second peak may reflect brain edema formation postponed by initial hypothermia. Both peaks may have triggered titration of sedation and osmotherapy. These observations corroborate the conclusion that hypothermia may be detrimental in malignant MCA stroke. Hypothermia is not a stand-alone treatment but a complex intervention with prolonged sedation, mechanical ventilation, and excess osmotic therapy, which combined put patients at risk of harm.
Limitations
Despite the randomized controlled design, our study has several limitations. The small sample size, owing to the premature stoppage of the trial, might not allow the detection of sig- 
Control
Body temperatures (A) and intracranial pressure (B) course throughout the first 14 days after randomization. Curves are based on the mean temperature per day in each group; vertical bars indicate SDs. Baseline temperature was normal in both groups at day 1. Hypothermia was induced at day 1. Target temperature was reached in 89% of patients and maintained for a minimum of 72 hours in every patient receiving the assigned treatment. Intracranial pressure curves are based on the mean intracranial measurement per day in each group. Increased intracranial pressure was defined as increase over 20 mm Hg (horizontal line) for a period longer than 10 minutes.
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Hypothermia in Addition to Decompressive Hemicraniectomy in Malignant Middle Cerebral Artery Stroke nificant differences concerning safety and efficacy measures. Because the trial was stopped early, these data do not warrant a formal futility statement. However, the homogenous results as well as comparable findings in other trials on hypothermia do support the validity of these observations. The open-label design of the study and the considerable number of protocol violations might have made the study prone to detection and attrition bias. On the other hand, end point assessments were conducted by blinded raters, and detection bias and attrition bias usually distort results in favor of the investigational treatment. Finally, because hypothermia is an intervention that follows biologically plausible rules, such as dose-response association, protocol violations regarding target temperature should have resulted in fewer SAEs. Thus, the analysis should have underestimated rather than overestimated the real risk of hypothermia.
Conclusions
This study suggests that moderate hypothermia does not improve survival or disability status in patients with malignant MCA stroke treated with early hemicraniectomy. Instead, the study suggests a higher rate of SAEs and probably poorer outcomes under hypothermic treatment. We cannot exclude the possibility that hypothermia may be of benefit in different settings of stroke treatment, including initiation and duration of hypothermia or target temperature or in different stroke subtypes. Currently, the use of hypothermia cannot be recommended in patients with malignant MCA stroke outside clinical trials. Correction: This article was corrected on February 25, 2019, to correct several errors. In the byline, an additional degree, MSc, was added after the name of Eric Jüttler, MD. In the Results section, the phrase "enrolled in the trial between August 2011 and September 2016" has been edited to end with "September 2015"; enrollment ended in that month, although data collection continued for an additional year. In addition, the sentence "Cardiovascular and nervous system SAEs are listed in the eTable in Supplement 1" was deleted because the accompanying eTable was no longer presented in the Supplement. Table 1 , the row header "Modified Rankin scale score on admission" was modified to "Preexisting modified Rankin scale score on admission." In Table 2 , the number of patients with SAE at 12 months was edited from 14/23 (61) to 10/23 (43). In Figure 1 , the number 154 (for patients who did not fulfill inclusion criteria) was modified to 199. In Figure 3 , the x-axis labeled was corrected from "Patients, %" to "Patient Groups," and the caption was updated to correct the phrase "…1 (4%) had a score of 54, and 3 (13%) had a score of 5" to "…1 (4%) had a score of 5, and 3 (13%) had a score of 6." A secondary end point was functional outcome at 12 months according to the modified Rankin scale. The figure shows the raw distribution of modified Rankin scores at 12 months; of the 23 participants in the control group, 1 (4%) had a score of 2, 6 (26%) had a score of 3, 12 (52%) had a score of 4, 1 (4%) had a score of 5, and 3 (13%) had a score of 6. Of the 25 participants in the hypothermia group, 6 (24%) had a score of 3, 10 (40%) had a score of 4, 3 (12%) had a score of 5, and 6 (24%) had a score of 6. This supplementary material has been provided by the authors to give readers additional information about their work.
eMethods.
List of further exclusion criteria: clinical signs of transtentorial herniation, coma indicated by a score of less than six on the Glasgow Coma Scale (GCS), secondary symptomatic hemorrhage in the area of the infarction with space-occupying effect (PH2), known contraindications for hypothermia such as hematological and bleeding disorders, severe cardiac, liver or kidney disease, sepsis, life-expectancy of less than three years, and pregnancy
eResults.
List of (cardiovascular and nervous system) severe adverse events (SAE): Cardiovascular SAE were bradycardia x1, deep vein thromobosis x1, unstable tachyarrhythmia x1, myocardial infarction x1, cardiac pulmonary edema x1, and cardiopulmonary resuscitation x4 in the hypothermia group and deep vein thrombosis x1, cardiopulmonary rescuscitation x1, and myocardial infarction x1 in the control group.
Nervous system SAE were subdural hygroma x1, epileptic seizure x1, re-infarction x1, parenchymal hematoma (PH2) x2, and transtentorial herniation x4 in the hypothermia group and subdural hematoma x1, epileptic seizure x2, and transtentorial herniation x3 in the control group. The preliminary statistical analysis plan was drafted during planning and beginning of the study and 41 finalized after early stopping of the trial for safety reasons. 
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Introduction 54
In patients with space-occupying middle cerebral artery (MCA) infarction therapeutic hypothermia (TH) 55 has been suggested additionally to decompressive hemicraniectomy (DHC). However, no sufficient 56 evidence for the benefit of TH was available. Therefore, our objective was to conduct a trial to examine 57 mortality and safety for patients that received TH in addition to DHC.
59
Study Methods 60
Trial design
61
The DEPTH-SOS trial is a multicentre, randomized controlled trial in six German academic centres to 62 evaluate the effect of hypothermia (32-34°C, >72h) in addition to (DHC) (<48h) in adult MCA stroke 63 patients (18 -60 years) on mortality at day 14 after DHC (primary endpoint). Additionally, safety 64 measures at day 14 and at 12 months, and functional parameters and mortality at 12 months are ana-65 lyzed.
67
Randomization
68
Randomization is computer generated in blocks and stratified for centers using a web-based system 69 (www.randomizer.at). Patients are assigned in a 1:1 ratio to either hemicraniectomy (control group) or 70 hemicraniectomy plus therapeutic hypothermia (hypothermia group). The trial has an open-label de-71 sign. Blinded rater obtaine follow-up-information after 12 months using a structured telephone inter-
72
view. An independent institute of statistics analyzes the data.
74
Sample size
75
Sample size is to be 324 patients. For the calculation see the study protocol. 
86
Timing of final analysis
87
The final analysis is to be conducted when all patients have reached their respective 1-year follow-up.
89
Timing of outcome assessments
90
Mortality is measured when a patient dies, adverse events are measured when they occurre. Pneu-91 monia is not accounted as SAE but as AE of special interest and is assessed after 14 days. 
98
Daily assessments include body temperature, intracranial pressure, CTs and MRIs y/n, pO2 value, 99 medication y/n, osmotherapy y/n, and therapeutic ventilation y/n.
101
Statistical Principles 102
Confidence intervals and P values 103
The level of statistical significance is 5% for all analyses. There are no adjustments for multiple testing.
104
Confidence intervals are at a 95% level, calculated via binomial distribution for dichotomous outcomes.
105
Confidence intervals for ORs are calculated using Fisher's exact test. For recurring events and inci-106 dence rates log-transformed confidence intervals are calculated.
108
Analysis populations
109
The analysis is performed as intention-to-treat, with the crossover patients treated as having received 
114
Trial Population 115
Eligibility
116
Patients with space-occupying MCA infarction were eligible for the trial, if they were to receive early 117 DHC within 48h of symptom onset. Additionally, the following criteria had to be met: 
204
Pneumonia is rated as adverse event, not as SAE, because its rate in intubated ICU patients is report-205 ed to be 70% even under normothermia. 
301
 mRS
302
The modified Rankin Scale (mRS) is a tool used to measure disability after strokes. The score 303 ranges from 0 (perfectly healthy) to 6 (death as a consequence of the stroke).
304
 BI
305
The Barthel Index (BI) is a tool for the assessment of the autonomy of a patient, i.e., the ability to 306 eat, walk and take care of personal hygiene autonomously. It does not assess the ability to live 307 alone, because aspects like cooking, homemaking and social aspects are not considered. The 308 scale ranges from 0 to 100, with higher scores relating to higher autonomy.
309
 p-value
310
The p-value is interpreted as the conditional probability of an observation given that the null 311 hypothesis is true. 4 Therefore the null hypothesis is dismissed at level , if the p-value of the 312 corresponding statistical test is less than or equal to . This means, with a maximum probability of 313 we hold on to the null, even if it is false. Formally, for a test statistic T, the calculated 314 value t of the test statistic and the null hypothesis , the p-value is given by 315 which yields a connection to the significance level . Let c be the the critical value, for which 316
holds. Comparing both equations, it holds that
317
This means, the null is dismissed if and only if the calculated test statistic t is greater than the criti 318 cal level c.
320
Data and Study Design 321
The DEPTH-SOS trial is a prospective, multicenter, open randomized controlled clinical trial (RCT) to 322 evaluate the effectiveness of therapeutic hypothermia additionally to the standard therapy, which is the 323 operative removal of a part of the skull, after a malignant middle cerebral artery infarction (most severe, life-threatening stroke). The main question was, if additional TH could decrease mortality in 325 stroke patients. The duration of the TH will be at least 72 hours with a target temperature of ,
326
starting early within 12 hours after surgery.
327
According to sample size estimation and an expected absolute therapy effect of 12% 328 patients were included and assigned to the groups in a 1:1 ratio. The randomization of the patients 329 has been executed through permuted blocks of 6 patients each. Patients had to be between 18 and 60 330 years to be included in the trial. Patients with a preexisting disability (score higher than 1 on the 331 modified Rankin Scale (mRS)) or a preexisting impairment of daily activities (score below 95 on the
332
Barthel Index (BI)) were exluded from the trial. Another exclusion criterion was a score of less than 6 333 on the Glasgow Coma Scale (GCS), indicating a deep coma. analysis, planned after 50 patients, possible differences between treatment groups were to be 338 indicated by Pocock's alpha-spending function. The interim analysis was cancelled due to the 339 premature end of the study, instead the final analysis was conducted.
340
The primary endpoint was the mortality and safety analysis at d14 within the intention-to-treat (ITT) 341 population. Since there were two crossover patients in the already small population, a per-protocol
342
(PP) analysis of the primary and safety endpoints at day 14 was also conducted, with the data 
358
Data Sets 359
Since in the randomized groups all known and unknown confounders are equally distributed, the focus 360 was laid mostly on the ITT data set, i.e., the two crossover patients were included in our analyses and 361 treated as if they were in their respective original group. Due to the small number of observations, 362 deliberations about a possible bias from the crossover patients werde made, viz. if all SAEs would 363 have occurred to them, whereas they did not get the hypothermia treatment. Therefore two additional 364 analyses were conducted. In a second analysis, the PP approach was used for main mortality and safety endpoints, where these two patients were excluded from the analysis to see whether the 366 exclusion influences any outcome at all. Finally, the as-treated analysis was conducted where the two 367 crossover patients were added in the control group.
368
The ITT data set has a size of 50 patients, with 26 being in the hypothermia group, and 24 in the 369 control group. The PP data set has a total of 48 patients, with 24 in each group. The as-treated data 370 set has 26 in control and 24 in hypothermia.
372
Odds Ratio 373
Since the data used for the Odds Ratio (OR) is binomially distributed, binomial estimates for the 374 mortality after 14 days were calculated. The OR is a ratio of the odds of the occurrence of an outcome 375 of interest between both groups. The OR ranges from 0 to 1, where an OR of 1 means that there is no 376 difference between groups. The higher the value, the higher the odds for the occurrence of the 377 outcome in the first group. Let be the probability for a patient in the experimental group to have the 378 outcome and be the probability of a patient in the control group. The OR is then defined by
379
When estimating the OR for confidence intervals, binomial estimates for were used, instead.
380
This calculation of the OR is valid for large populations. Given small numbers in the 2 by 2 table, the
381
OR can have a great variance or even be biased. Therefore, another estimator was used that 
395
For recurring events like medication over the first 14 days the IR was used for group comparison. For 396 the confidence intervals a log-transformation was performed to minimize data variability.
398
Nelson-Aalen Estimator 399
The 
424
Median and Interquartile Range 425
The median of a distribution is the value of a distribution function for which holds 426 and lim i.e., the median is the value , for which the distribution function is at least 0.5 and the left-hand limit 427 is smaller than or equal to 0.5. In the case of a non-continuous function like the ECDF, the first value
428
, for which the ECDF exceeds 0.5, is taken. In the case of patients reaching the target temperature, 429 the median tells us when 50% of the patients have reached that target temperature. Median was 430 chosen over mean, since the median is more robust in case the distribution is not symmetrical. The
431
IQR is the range between the first and the third quartile of the distribution function, i. e., the 0.25% 432 quantile and the 0.75% quantile.
434
Binomial Estimator and the Binomial Test 435
The binomial estimator is used when looking at proportions in a population or between populations. It 436 is based on the binomial distribution with point probability
437
where is the success probability in one trial, and is the number of trials. In our case, is the 438 probability of an event in a population of size . The estimator is then given by the number of events 439 divided by the size of the population.
440
For large , the Central Limit Theorem can be used to approximate the binomial distribution by a 
459
Multinomial Logistic Model 460
For the analysis of the covariates 'age', 'sex', 'stroke severity' and 'time from randomization to 461 hemicraniectomy in hours', a multinomial logistic model for ordinal and/or nominal variables was used.
462
The variables here were ordinal with the exception of the nominal 'sex'. The goal was to estimate the 463 probability of a patient to die within 14 days. 
Log-rank Test 535
The log-rank test is widely used to compare two survival curves. The test compares two groups at 536 each death time and the expected number of deaths proportional to the population at risk at a specific 537 time. 3 The result is then summed up over all death times and compared with the respective observed 538 number of deaths. 
547
The log-rank test is non-parametric, meaning that there is no assumption about the specific distribution 548 of the data, it is only assumed that both groups have the same survival function. The log-rank test was 
560
Analyses for NIHSS, GCS, BI and the mRS 561
For the NIHHS and GCS scores two different analyses were conducted, because there is no separate 562 coding for deceased patients. In the NIHHS the scale ranges from 0 to 42, where higher scores mean 563 more severe strokes. Therefore in the first analysis of the NIHSS score deceased patients were 564 excluded. In a second analysis, the sensitivity analysis, the deceased patients were included and 565 assigned a score of 42 to not condition on the future, i.e., no assumptions about the life status 566 of patients were made.
567
The same approach for the GCS was made, which ranges from 3 to 15, where lower scores indicate 568 more severe coma. In the first analysis of this score deceased patients were again excluded, and in 569 the second the patients were included and assigned a score of 3.
570
The BI ranges from 0 to 100, where higher scores relate to higher autonomy. Only a descriptive 571 analysis was conducted for this score due to missing data.
572
The mRS ranges from 0 to 6, where a higher score indicates a more severe disability following a 573 stroke, with 6 being the score for death.
575
Cox' Proportional Hazards Model 576
Cox' proportional hazards model is used for regression of survival data similar to the usual linear or 577 logistic regression. It also gives us the estimated hazard ratio between two groups, so we can see if 
593
The coxph function calculates the estimated logarithmic hazard ratio and the actual hazard ratio along 594 with the confidence interval for the hazard ratio. Additionally, it calculates three statistical tests for the 595 significance of the HR, the Wald test, the likelihood ratio test, and the score test, which is equivalent to 596 the log-rank test.
3 597 598
Statistical Analysis 599
Data 600
The DEPTH-SOS trial randomized 50 adult patients up to 60 years to either therapeutic hypothermia 601 (26 patients, hypothermia group) or standard care (24 patients, control group). Since there were two 602 crossover patients from the hypothermia group to the control group, an ITT approach was performed
603
for the first analysis. In a second stept, a PP analysis and an as-treated analysis of mortality and 604 safety were performed.
605
First of all a univariate analysis of the primary endpoint 'Mortality at d14' was performed. Therefore,
606
only covariates from the baseline data (see Table 4 .1) was used as well as for the multivariate 607 analyses.
609
Endpoints 610
 Primary endpoint
611
The primary endpoint is mortality at d14. It was analyzed dichotomously with a binomial estimate 612 by group with exact 95% CIs. Exact 95% CIs for the OR using Fisher's test were also computed.
613
Additionally, same method was used to test for independence between mortality and group 614 membership. In addition, -tests were used as sensitivity analysis to verify the exact results.
615
Then, multivariate analyses were conducted with baseline covariates 'age', 'sex', 'stroke severity', 616 and 'time from randomization to hemicraniectomy'. The age variable was converted into an 617 analyzed in decades, meaning the age of each patient was divided by 10. Our method here was 618 logistic regression with four bivariate models, in which group membership was always included in 619 addition to one of the baseline variables. Afterwards a model with group membership and all four 620 baseline variables was set up. Outcome was again mortality at d14.
621
Finally, a multivariate analysis was conducted, where all variables which fulfilled the AKAIKE 622 criterion (univariate p-value 15.7%) were included. The method of choice was again logistic 623 regression.
624
 Secondary endpoints at d14 
661
'End stay in intensive care dead'), due to competing risks.
663
The following recurring events were analyzed with incidence rates and according 
